Adeola Adedokun
Adeola Adedokun has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Angela Aifah
Section for Global Health; Department of Population Health & Institute for Excellence in Health Equity NYU Grossman School of Medicine New York New York USA
1 shared publication - Angela Attah
Akwa Ibom State Primary Healthcare Development Agency, Uyo, Nigeria
1 shared publication - Anyiekere Ekanem
University of Uyo Teaching Hospital, Uyo, Nigeria
1 shared publication - Daniel Henry
Cardiovascular Research Unit, University of Abuja Teaching Hospital, Abuja, Nigeria
1 shared publication - Daphne Lew
Center for Biostatistics and Data Science, Washington University in St. Louis School of Medicine, St. Louis, Missouri (D.L.)
1 shared publication - Deborah Onakomaiya
Department of Population Health, NYU Grossman School of Medicine, New York, USA
1 shared publication
Latest Publications
- Open Access
- 17 March 2026
- Published by Elsevier in SSRN Electronic Journal
Managing Hypertension Among People Living With HIV: A Stepped-Wedge Cluster Randomized Trial of an Integrated Model in Nigeria
Background: Task strengthening strategy for systolic hypertension control (TASSH) is effective in Africa but its adoption as an integrated care model for hypertension management in people living with HIV (PLWH) is not established.Methods: This stepped-wedge multi-site cluster randomised trial compared self-directed care (SDC) vs practice facilitation (PF) as implementation strategies for integrating TASSH into HIV care in 30 primary healthcare centers (PHCs) providing HIV services in Nigeria.PLWH with uncontrolled hypertension (systolic BP (SBP) 140-179 mmHg or diastolic BP 90-100 mmHg) were enrolled between Oct 2022 and March 2023 and followed through October 2025. All PHCs initially implemented TASSH using SDC for at least 3 months, during which nurses were trained on the TASSH protocol, including hypertension screening and diagnosis, monthly lifestyle counseling, initiation and titration of antihypertensive medications. PHCs then transitioned according to a randomised sequence to PF, in which nurses received coaching and performance feedback. The primary outcome was clinic-level TASSH adoption; secondary outcomes were SBP and BP control (BP <140/90 mmHg) 12 months after PF initiation. Trial is registred with ClinicalTrials.gov NCT05031819.Findings: Of 954 PLWH enrolled (mean age 49.2 years [SD 10.8]; 71% women; baseline SBP 152.6 mmHg [SD 10.5]), TASSH Adoption was 98.8% (95% CI 97.7 to 99.9) during SDC and 99.6% (97.5 to 100.0) 12 months after PF initiation (adjusted difference 0.8%, 95% CI −1.6 to 3.1). Mean SBP decreased to 127.4 mm Hg during SDC and 124.7 mm Hg after PF initiation (adjusted difference −2.7 mm Hg, 95% CI −4.5 to −0.8). BP control was 85.3% and 90.6%, respectively (adjusted difference 6.0%, 95% CI −0.01 to 0.11). Thirty nine serious adverse events occurred with none related to the interventions.Interpretation: Findings from this multisite trial demonstrate a near universal adoption of a nurse-led integrated care model for treatment of hypertension in primary care practices among PLWH in Nigeria.
- 17 March 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessManaging Hypertension Among People Living With HIV: A Stepped-Wedge Cluster Randomized Trial of an Integrated Model in Nigeria
Background: Task strengthening strategy for systolic hypertension control (TASSH) is effective in Africa but its adoption as an integrated care model for hypertension management in people living with HIV (PLWH) is not established.Methods: This stepped-wedge multi-site cluster randomised trial compared self-directed care (SDC) vs practice facilitation (PF) as implementation strategies for integrating TASSH into HIV care in 30 primary healthcare centers (PHCs) providing HIV services in Nigeria.PLWH with uncontrolled hypertension (systolic BP (SBP) 140-179 mmHg or diastolic BP 90-100 mmHg) were enrolled between Oct 2022 and March 2023 and followed through October 2025. All PHCs initially implemented TASSH using SDC for at least 3 months, during which nurses were trained on the TASSH protocol, including hypertension screening and diagnosis, monthly lifestyle counseling, initiation and titration of antihypertensive medications. PHCs then transitioned according to a randomised sequence to PF, in which nurses received coaching and performance feedback. The primary outcome was clinic-level TASSH adoption; secondary outcomes were SBP and BP control (BP <140/90 mmHg) 12 months after PF initiation. Trial is registred with ClinicalTrials.gov NCT05031819.Findings: Of 954 PLWH enrolled (mean age 49.2 years [SD 10.8]; 71% women; baseline SBP 152.6 mmHg [SD 10.5]), TASSH Adoption was 98.8% (95% CI 97.7 to 99.9) during SDC and 99.6% (97.5 to 100.0) 12 months after PF initiation (adjusted difference 0.8%, 95% CI −1.6 to 3.1). Mean SBP decreased to 127.4 mm Hg during SDC and 124.7 mm Hg after PF initiation (adjusted difference −2.7 mm Hg, 95% CI −4.5 to −0.8). BP control was 85.3% and 90.6%, respectively (adjusted difference 6.0%, 95% CI −0.01 to 0.11). Thirty nine serious adverse events occurred with none related to the interventions.Interpretation: Findings from this multisite trial demonstrate a near universal adoption of a nurse-led integrated care model for treatment of hypertension in primary care practices among PLWH in Nigeria.